Josh Armenia on Results of Mutated Gene Analysis in Prostate Cancer
Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.
Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.
A mutational significance analysis was conducted to detect novel genes and pathways in 918 patients with prostate cancer. The goal of the study was to redefine the genomic landscape of prostate cancer, says Armenia.
Twenty-three novel genes were identified that were not previously found to be significantly mutated in prostate cancer, but were recurrent in other cancers, such as SPEN in breast cancer. Frequent truncating mutations in key regulators of the SWI/SNF complex such as SMARCA1, ARID1A, ARID1B, and ARID2 were also identified, as well as an enrichment in splicing pathway alterations in SF3B1 and U2AF1.
According to Armenia, this analysis provides a broader persepective of pathways to consider in the treatment of patients with prostate cancer.
<<<
